Research team receives 65 million for EURO SHOCK heart attack study
A team of researchers at the NIHR Leicester Biomedical Research Centre, UK - a partnership between Leicester’s Hospitals, the University of Leicester and Loughborough University - has been awarded €6.5 million from the Horizon 2020 European Commission fund.
The team, led by clinical scientist consultant Professor Anthony Gershlick (pictured) from our Department of Cardiovascular Sciences, will investigate the impact of using Extracorporeal Membrane Oxygenation (ECMO) on the outcomes of patients who have had a severe heart attack.
ECMO is a machine that acts as an artificial heart and lungs to provide oxygen to the blood and remove waste gases. The blood is pumped using a motor. This allows the patient’s heart and lungs the time to rest and repair themselves.
Professor Gershlick, Professor of Interventional Cardiology at the University of Leicester and Consultant Cardiologist at Leicester’s Hospitals, explained: “Between 8-10% percent of patients who have heart attacks suffer from cardiogenic shock, such that their hearts fail to pump properly. In such cases, the mortality rate can be as high as 50 percent in the first 3 months after the heart attack. ECMO is sometimes used to treat these patients, but it is often deployed too late and their heart is already very weak. We will investigate whether using ECMO on patients that suffer from cardiogenic shock immediately after their heart attack will reduce mortality rates and improve their outcomes. There has been world-wide interest in our proposal especially from the USA. There will be a number of sub-studies that could have far reaching impact on other groups of unwell patients, such as specific MRI proposals.”
Leicester will be the lead centre, coordinating the study in 11 other sites across Europe, including Germany, Norway and Spain.
Professor Philip Baker, Pro-Vice-Chancellor and Head of the College of Life Sciences at the University of Leicester, said: “This award is a fantastic achievement. Professor Gershlick has done remarkably well to secure funding for this large and important trial led from Leicester. Despite the uncertainties in European funding, the College of Life Sciences at the University of Leicester has been extremely successful in obtaining European funding for Biomedical Research. This award is a further example of Leicester’s success in leading transformative Medical Research.”
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754946.